Axatilimab Demonstrates Effectiveness in Refractory/Recurrent GVHD.

Published Date: 15 Dec 2023

lowest dose produced the least amount of toxicity and the highest overall response rate.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer

2.

Next-Generation KRAS G12C Inhibitor Shows 'Robust' Efficacy in Advanced Lung Cancer

3.

PSA Testing Is Not Enough for Another Candidate for Prostate Cancer Screening.

4.

Durvalumab Wins FDA Approval in Limited-Stage SCLC

5.

Single-dose radiation before surgery can eradicate breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot